NEW
Comirnaty復必泰

Comirnaty

Manufacturer:

BioNTech

Distributor:

Pharmason

Marketer:

Fosun Pharma
Concise Prescribing Info
Contents
COVID-19 mRNA vaccine (BNT162b2) (embedded in lipid nanoparticles)
Indications/Uses
Active immunisation in individuals ≥16 yr to prevent COVID-19 caused by SARS-CoV-2 virus.
Dosage/Direction for Use
IM 2 doses (0.3 mL each) at least 21 days apart.
Contraindications
Special Precautions
Do not inj intravascularly, SC or intradermally. No available data on interchangeability w/ other COVID-19 vaccines; individuals who received 1st dose should receive 2nd dose to complete the vaccination course. Close observation for at least 15 min following vaccination; do not give 2nd dose if anaphylaxis to 1st dose occurred. Postpone vaccination in individuals suffering from acute severe febrile illness or acute infection. Bleeding or bruising may occur following IM administration; caution in individuals receiving anticoagulant therapy or those w/ thrombocytopenia or any coagulation disorder (eg, haemophilia). Duration of protection is still being determined by ongoing clinical trials. May not protect all vaccine recipients; individuals may not be fully protected until 7 days after 2nd dose. Immunocompromised individuals. Pregnancy & lactation. Childn & adolescents <16 yr.
Adverse Reactions
Headache; arthralgia, myalgia; inj site pain, fatigue, chills, pyrexia, inj site swelling. Nausea; inj site redness.
ATC Classification
J07BX - Other viral vaccines ; Used for active immunizations.
Additional Information
Emergency use authorization granted by the Secretary for Food and Health: January 25, 2021
Presentation/Packing
Form
Comirnaty concentrate for dispersion for inj 30 mcg (0.3 mL)/dose x 5 doses
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in